tickdelta
Sign in
Screener / SEC EDGAR /CIK 0000882095 /10-K filed Feb 24, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
BDXAMGNMDTGILDGEHCDHR
Nasdaq Health care · Biotechnology

Gilead Sciences GILD

GILD quote by TradingView
Employees
17,000
Headquarters
Foster City, CA
CEO
Daniel Patrick O'Day
Next results
around Feb 9, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $29.4B through the costs to a net profit of $8.5B · income statement of the 10-K

34% operating margin
Revenue to Gross profit: $23.2BRevenue to Cost of revenue: $6.2BGross profit to Operating profit: $10.0BGross profit to Operating expenses: $13.2BOperating profit to Net profit: $8.5BOperating profit to Tax & other: $1.5BOperating expenses to R&D: $5.8BOperating expenses to Sales, admin & other: $7.4B Revenue: $29.4B REVENUE $29.4B +2% Y/Y Gross profit: $23.2B · 79% margin GROSS PROFIT $23.2B 79% margin Cost of revenue: $6.2B · 21% of revenue COST OF REVENUE $6.2B 21% of revenue Operating profit: $10.0B · 34% margin OPERATING PROFIT $10.0B 34% margin · +503% Y/Y Operating expenses: $13.2B · 45% of revenue OPERATING EXPENSES $13.2B 45% of revenue Net profit: $8.5B · 29% margin NET PROFIT $8.5B 29% margin · +1673% Y/Y Tax & other: $1.5B · 5% of revenue TAX & OTHER $1.5B 5% of revenue R&D: $5.8B · 20% of revenue R&D $5.8B 20% of revenue Sales, admin & other: $7.4B · 25% of revenue SALES, ADMIN & OTHER $7.4B 25% of revenue
Gross profit $23.2B 79% margin
Operating profit $10.0B 34% margin · +503% Y/Y
Net profit $8.5B 29% margin · +1673% Y/Y
The full income statement, year by year

GILD among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.

Compare
Revenue growth: 2.4%, above 22% of 59 peers (their median 7.2%) REVENUE GROWTH 2.4% · above 22% Gross margin: 79.9%, above 90% of 50 peers (their median 64.2%) GROSS MARGIN 79.9% · above 90% Operating margin: -7.6%, above 2% of 50 peers (their median 13.7%) OPERATING MARGIN -7.6% · above 2% Net margin: -12.5%, above 2% of 59 peers (their median 9.7%) NET MARGIN -12.5% · above 2% FCF margin: 44.5%, above 100% of 55 peers (their median 15.2%) FCF MARGIN 44.5% · above 100% Return on capital: 22.2%, above 93% of 41 peers (their median 9.0%) RETURN ON CAPITAL 22.2% · above 93%
GILD Peer median Below the median

What changed

13 new risk paragraphs. 10-K filed Feb 24, 2026 against Feb 28, 2025.

Risk factors
13 new paragraphs, nothing like them in the previous 10-K
10-K Item 1A
Accounting checks
11 other checks clear
10-K · XBRL
Insiders
No open-market buys in the last 90 days
Form 4
Filings
8 in the last 30 days
EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 11 checks found nothing to note

  • Receivables +11.2% vs revenue +2.4% (+8.8 pts)
  • Cash from operations $10.0B vs net income $8.5B (FY ending Dec 31, 2025)
  • Inventory +3.7% vs revenue +2.4% (+1.3 pts)
8 more checks with nothing to note
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No longer listed: Valuation of in-process research and development intangible asset. Same as last year: Government and commercial rebates
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

13 paragraphs in Risk Factors that were not in the 10-K filed Feb 28, 2025. Quoted as filed.

All 13 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    In addition, future cell therapy products may be subject to a Risk Evaluation and Mitigation Strategy (“REMS”), which is a drug safety program that the U.S. Food and Drug Administration (“FDA”) may require for certain drugs. For example, until June 2025, Yescarta and Tecartus were subject to a REMS requirement to manage the risks of…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    Additionally, we face public attention and scrutiny related to the complex decisions we make concerning the pricing, global supply and distribution, allocation and intellectual property of our commercialized products, as well as other factors that may contribute to patient access to our medicines, all of which may adversely affect our…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    A significant portion of the raw materials and intermediates in the manufacturing of our products and product candidates are supplied by third-party suppliers, manufacturers and corporate partners outside of the U.S. As a result, any geopolitical or economic factors in a specific country or region, including any new, or changes in or…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    Our suppliers and third-party manufacturers and corporate partners similarly face these risks that could have an adverse effect on our business, and any disruption to their operations could have an adverse effect on our manufacturing and supply chain.

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$27.3B$27.1B$28.8B$29.4B
Net income$4.6B$5.7B$480.0M$8.5B
Operating cash flow$9.1B$8.0B$10.8B$10.0B
Free cash flow$8.3B$7.4B$10.3B$9.5B

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$29.4B ▲ 2.4% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

8 filings in the last 30 days · SEC EDGAR

All filings
3 more

About the company

Gilead Sciences, Foster City, CA · from the 10-K filed Feb 24, 2026

Gilead Sciences, Inc. (including its consolidated subsidiaries, referred to as “Gilead,” the “company,” “we,” “our” or “us”) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California.

Headquarters
Foster City, CA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Oct 29, 2026
Incorporated in
DE

Employees, at the top of the page: "As of December 31, 2025, Gilead had approximately 17,000 employees" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 24, 2026 (open at SEC), compared with the 10-K filed Feb 28, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GILD/export.csv") into a cell.